Mereo BioPharma (MREO) Other Non-Current Liabilities (2017 - 2026)

Mereo BioPharma (MREO) has 10 years of Other Non-Current Liabilities data on file, last reported at $28000.0 in Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $28000.0, down 73.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $28000.0 (down 73.33% YoY), and the FY2025 annual result was $38000.0, down 93.27% from the prior year.
• Other Non-Current Liabilities retreated to $28000.0 in Q1 2026 per MREO's latest filing, from $38000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $925000.0 in Q2 2024 and troughed at $28000.0 in Q1 2026.
• A 5-year average of $398711.4 and a median of $412000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 805.56% in 2025 and fell as far as 93.27% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $622824.9 in 2022, then tumbled by 33.85% to $412000.0 in 2023, then soared by 37.14% to $565000.0 in 2024, then sank by 93.27% to $38000.0 in 2025, then dropped by 26.32% to $28000.0 in 2026.
• Business Quant data shows MREO's Other Non-Current Liabilities at $28000.0 in Q1 2026, $38000.0 in Q4 2025, and $652000.0 in Q3 2025.